...
首页> 外文期刊>Surgery >Adenovirus-mediated overexpression of human tissue plasminogen activator prevents peritoneal adhesion formation/reformation in rats.
【24h】

Adenovirus-mediated overexpression of human tissue plasminogen activator prevents peritoneal adhesion formation/reformation in rats.

机译:腺病毒介导的人类组织纤溶酶原激活剂的过度表达可防止大鼠腹膜粘连的形成/重构。

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND: Tissue-plasminogen activator (tPA) demonstrated beneficial effects on peritoneal adhesion formation; however, its short half-life limits its continual fibrinolytic effect. Therefore, we delivered adenovirus encoding tPA to prevent adhesions. METHODS: Rats were subjected to peritoneal injury and assigned to two protocols. In de novo adhesion protocol, adenovirus encoding human tPA gene (Ad-htPA) was instilled after peritoneal injury in group 1 (n = 22), whereas group 2 received phosphate-buffered saline (PBS) (n = 24). In recurrent adhesion protocol, group 1 (n = 15) received the same Ad-htPA dose after adhesiolysis and group 2 (n = 13) received PBS. Adhesion severity was scored 1 week after ad-htPA instillation. Adhesions were analyzed for htPA mRNA by reverse transcription-polymerase chain reaction and levels of htPA, and fibrinolytic inhibitors PAI-1, TIMP-1, and TGF-beta1 were measured using enzyme-linked immunosorbent assay. RESULTS: htPA mRNA and protein were only expressed in adhesions from treated groups. A reduction in adhesion scores (P < .01) and in fibrinolytic inhibitors (P < .001) occurred in the treatment groups. Also, negative correlation was found (r = -.69, P < .01) between adhesion scores and htPA protein, but a positive correlation was found (r = .90, P < .01) between adhesion score and fibrinolytic inhibitors. No bleeding or wound complications were encountered. CONCLUSION: Administration of adenovector encoding htPA is safe and decreased de novo and recurrent peritoneal adhesions.
机译:背景:组织纤溶酶原激活剂(tPA)对腹膜粘连形成具有有益作用。但是,其半衰期短限制了其持续的纤溶作用。因此,我们提供了编码tPA的腺病毒以防止粘连。方法:大鼠遭受腹膜损伤并分为两种方案。在从头粘附方案中,第1组(n = 22)腹膜损伤后滴注编码人tPA基因的腺病毒(Ad-htPA),而第2组接受磷酸盐缓冲液(PBS)(n = 24)。在复发性粘附方案中,第1组(n = 15)在粘着溶解后接受相同的Ad-htPA剂量,而第2组(n = 13)接受PBS。在ad-htPA滴注后1周对粘附强度进行评分。通过逆转录-聚合酶链反应分析htPA mRNA的黏附力和htPA的水平,并使用酶联免疫吸附测定法测定纤溶抑制剂PAI-1,TIMP-1和TGF-β1。结果:htPA mRNA和蛋白仅在治疗组的粘连中表达。在治疗组中,黏附评分(P <.01)和纤溶抑制剂(P <.001)降低。同样,粘附分数和htPA蛋白之间发现负相关(r = -.69,P <.01),而粘附分数和纤溶抑制剂之间发现正相关(r = .90,P <.01)。没有遇到出血或伤口并发症。结论:编码htPA的腺载体的给药是安全的,可减少从头和复发性腹膜粘连。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号